10-QHealthcare

Fulgent Genetics, Inc.

FLGT · Period ending 2026-09-30 · Filed 2026-11-05 · Updated

In short

Fulgent Genetics, Inc. (FLGT) has revenue up 13.8% to $322.7M and net income down 41.7% to -$60.5M year on year. Its net margin is -18.8% and gross margin 40.6%. Fisclear flags 2 high-severity risks, led by: Net loss of $60.5M — the company spent more than it earned. Investors should monitor the path to profitability. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$24.12

P/B

0.7x

Price ÷ book value

P/S (TTM)

2.0x

Price ÷ revenue per share

Beta

1.02

Moderate market correlation

52-Week Range

$13.46$24.12 now$31.04

Decision Context

Below-average scores in Efficiency, Cashflow. The data points to fundamental challenges that outweigh near-term macro considerations.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

FLGT vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.1%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.1%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — FLGT

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Gross Profit: $130.9M (+22.1% YoY) — Gross profit rose 22% — the spread between revenue and direct costs improved.

  • Revenue: $322.7M (+13.8% YoY) — Revenue grew 14% — the company sold more goods or services than the prior year.

◈

Weaknesses

  • Operating Cash Flow: -$101.6M (-582.6% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.

  • Net Income: -$60.5M (-41.7% YoY) — The company posted a net loss — total expenses exceeded total revenue.

  • Total Assets: $1.2B (-0.5% YoY) — Total assets shrank 1% — the balance sheet contracted.

  • Price-to-book ratio of 0.64x — stock trades below book value, which may indicate market concerns about asset quality or profitability.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Net loss of $60.5M — the company spent more than it earned. Investors should monitor the path to profitability.

  • Negative operating cash flow of $101.6M — the core business consumed more cash than it generated.

Year-over-Year Changes

Operating Cash Flow

-$101.6M

was $21.1M

−582.6%

Negative operating cash flow — the business consumed more cash than it produced from operations.

Net Income

-$60.5M

was -$42.7M

−41.7%

The company posted a net loss — total expenses exceeded total revenue.

Gross Profit

$130.9M

was $107.2M

+22.1%

Gross profit rose 22% — the spread between revenue and direct costs improved.

Revenue

$322.7M

was $283.5M

+13.8%

Revenue grew 14% — the company sold more goods or services than the prior year.

Total Assets

$1.2B

was $1.2B

−0.5%

Total assets shrank 1% — the balance sheet contracted.

Risk Flags

2 high · 0 medium · 1 low
  • ⚠ High

    Net loss of $60.5M — the company spent more than it earned. Investors should monitor the path to profitability.

  • ⚠ High

    Negative operating cash flow of $101.6M — the core business consumed more cash than it generated.

  • ○ Low

    Price-to-book ratio of 0.64x — stock trades below book value, which may indicate market concerns about asset quality or profitability.

Technical Signals

Daily closes · 1-year data

Fulgent Genetics, Inc.: common questions

Is Fulgent Genetics, Inc. profitable?

No. Fulgent Genetics, Inc. reported a net loss of $61M in its latest fiscal year (fiscal 2025), a net margin of -18.8%.

Is Fulgent Genetics, Inc.'s revenue growing?

Yes. Revenue grew 13.8% year on year, to $322.7M.

What is Fulgent Genetics, Inc.'s P/E ratio?

Fulgent Genetics, Inc. has no meaningful P/E ratio at the moment, because it lost money over the latest year. P/E only works when earnings are positive.

Does Fulgent Genetics, Inc. pay a dividend?

No dividend is currently expected from Fulgent Genetics, Inc., according to the latest market data.

What are the main risks for Fulgent Genetics, Inc.?

Fisclear's checks flag 2 medium- or high-severity risks. The most serious: Net loss of $60.5M — the company spent more than it earned. Investors should monitor the path to profitability.

Answers are generated from the figures in this report (updated 6 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — FLGT

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade FLGT

Links open broker research pages. Not an endorsement or recommendation.

Research Fulgent Genetics, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.